Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

Nature

Volumn 485, Issue 7398, 2012, Pages 321-326

  Manglik, Aashish ^a   Kruse, Andrew C ^a   Kobilka, Tong Sun ^a   Thian, Foon Sun ^a   Mathiesen, Jesper M ^a   Sunahara, Roger K ^b   Pardo, Leonardo ^c   Weis, William I ^a   Kobilka, Brian K ^a   Granier, Sébastien ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA FUNALTREXAMINE; DIMER; G PROTEIN COUPLED RECEPTOR; MU OPIATE RECEPTOR; NALTRINDOLE; SOLVENT;

ANTAGONISM; CHEMICAL BINDING; CRUSTAL STRUCTURE; DRUG; PROTEIN;

ALPHA HELIX; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; PRIORITY JOURNAL; PROTEIN MOTIF;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; LIGANDS; MICE; MODELS, MOLECULAR; MORPHINANS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, OPIOID, MU; SOLVENTS;

EID: 84861096654     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10954     Document Type: Article

References (47)

1. Katzung, B. G. Basic and Clinical Pharmacology 10th edn (LANGE McGraw Hill Medical, 2007).
2. Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the m-opioid-receptor gene. Nature 383, 819-823 (1996).
3. Lord, J. A., Waterfield, A. A., Hughes, J. & Kosterlitz, H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature 267, 495-499 (1977).
4. Raffa, R. B., Martinez, R. P. & Connelly, C. D. G-protein antisense oligodeoxyribonucleotides and m-opioid supraspinal antinociception. Eur. J. Pharmacol. 258, R5-R7 (1994).
5. Shukla, A. K., Xiao, K. & Lefkowitz, R. J. Emerging paradigms of b-arrestindependent seven transmembrane receptor signaling. Trends Biochem. Sci. 36, 457-469 (2011).
6. Molinari, P. et al. Morphine-like opiates selectively antagonize receptor-arrestin interactions. J. Biol. Chem. 285, 12522-12535 (2010).
7. Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural insights into b2-adrenergic receptor function. Science 318, 1266-1273 (2007).
8. Ballesteros, J. A. & Weinstein, H. Integrated Methods for the Construction of Three Dimensional Models and Computational Probing of Structure Function Relations in G Protein-Coupled Receptors Vol. 25 366-428 (Academic, 1995).
9. Chen, C. et al. Determination of the amino acid residue involved in [3H]bfunaltrexamine covalent binding in the cloned rat m-opioid receptor. J. Biol. Chem. 271, 21422-21429 (1996).
10. Huang, P. et al. Functional role of a conserved motif in TM6 of the rat m opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 40, 13501-13509 (2001).
11. Haga, K. et al. Structure of the humanM2muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551 (2012).
12. Kruse, A. C. et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552-556 (2012).
13. Disse, B. et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 52, 537-544 (1993).
14. Cassel, J. A., Daubert, J. D. & DeHaven, R. N. [3H]Alvimopan binding to the m opioid receptor: comparative binding kinetics of opioid antagonists. Eur. J. Pharmacol. 520, 29-36 (2005).
15. Kurowski, M., Rosenbaum, J. S., Perry, D. C. & Sadee, W. [3H]-etorphine and [3H]-diprenorphine receptor binding in vitro and in vivo: differential effect of Na1 and guanylyl imidodiphosphate. Brain Res. 249, 345-352 (1982).
16. Sporer, K. A. Acute heroin overdose. Ann. Intern. Med. 130, 584-590 (1999).
17. Alford, B. T., Burkhart, R. L. & Johnson, W. P. Etorphine and diprenorphine as immobilizing and reversing agents in captive and free-ranging mammals. J. Am. Vet. Med. Assoc. 164, 702-705 (1974).
18. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
19. Mansour, A. et al. Key residues defining the m-opioid receptor binding pocket: a site-directed mutagenesis study. J. Neurochem. 68, 344-353 (1997).
20. Bonner, G., Meng, F. & Akil, H. Selectivity of m-opioid receptor determined by interfacial residues near third extracellular loop. Eur. J. Pharmacol. 403, 37-44 (2000).
21. Zadina, J. E., Hackler, L., Ge, L. J. & Kastin, A. J. A potent and selective endogenous agonist for the m-opiate receptor. Nature 386, 499-502 (1997).
22. Seki, T. et al. DAMGO recognizes four residues in the third extracellular loop to discriminate between m-and k-opioid receptors. Eur. J. Pharmacol. 350, 301-310 (1998).
23. Rozenfeld, R., Gomes, I. & Devi, L. in The Opiate Receptors Vol. 23 (ed. Pasternak, G. W.) Ch. 15 407-437 (Humana, 2011).
24. Johnston, J. M. et al. Making structural sense of dimerization interfaces of d opioid receptor homodimers. Biochemistry 50, 1682-1690 (2011).
25. Fanelli, F. & De Benedetti, P. G. Update 1 of: computational modeling approaches to structure-function analysis of G protein-coupled receptors. Chem. Rev. 111, PR438-PR535 (2011).
26. Hebert, T. E. et al.A peptide derived froma b2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271, 16384-16392 (1996).
27. Granier, S. et al. A cyclic peptide mimicking the third intracellular loop of the V2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein. J. Biol. Chem. 279, 50904-50914 (2004).
28. Hu, J. et al. Structural aspects of M3 muscarinic acetylcholine receptor dimer formation and activation. FASEB J. 26, 604-616 (2011).
29. Park, J. H., Scheerer, P.,Hofmann, K. P.,Choe, H. W.&Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183-187 (2008).
30. He, S. Q. et al. Facilitation of m-opioid receptor activity by preventing d-opioid receptor-mediated codegradation. Neuron 69, 120-131 (2011).
31. Jordan, B. A. & Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700 (1999).
32. He, L., Fong, J., von Zastrow, M. & Whistler, J. L. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108, 271-282 (2002).
33. He, L. & Whistler, J. L. An opiate cocktail that reduces morphine tolerance and dependence. Curr. Biol. 15, 1028-1033 (2005).
34. George, S. R. et al. Oligomerization of m-andd-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275, 26128-26135 (2000).
35. Gomes, I., Ijzerman, A. P., Ye, K.,Maillet, E. L.&Devi, L. A.Gprotein-coupled receptor heteromerization: a role in allostericmodulation of ligand binding.Mol. Pharmacol. 79, 1044-1052 (2011).
36. Vilardaga, J. P. et al. Conformational cross-talk between a2A-adrenergic and m-opioid receptors controls cell signaling. Nature Chem. Biol. 4, 126-131 (2008).
37. Rasmussen, S. G. et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
38. Fung, J. J. et al. Ligand-regulated oligomerization of b2-adrenoceptors in a model lipid bilayer. EMBO J. 28, 3315-3328 (2009).
39. Golebiewska, U., Johnston, J. M., Devi, L., Filizola, M. & Scarlata, S. Differential response to morphine of the oligomeric state of m-opioid in the presence of d-opioid receptors. Biochemistry 50, 2829-2837 (2011).
40. Portoghese, P. S., Sultana, M. & Takemori, A. E. Design of peptidomimetic d opioid receptor antagonists using the message-address concept. J. Med. Chem. 33, 1714-1720 (1990).
41. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009).
42. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
43. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658-674 (2007).
44. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
45. Afonine, P. V., Grosse-Kunstleve, R. W. & Adams, P. D. A robust bulk-solvent correction and anisotropic scaling procedure. Acta Crystallogr. D 61, 850-855 (2005).
46. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010).
47. Schrodinger, L. The PyMOL Molecular Graphics System v.1.3r1. (2010).